I
Tepkinly is now
licensed for 3L+ DLBCL
Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly has a conditional marketing authorisation
- further data awaited.
You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.
Adverse event reporting information can be found at the bottom of this page.
Tepkinly is now licensed for 3L+ DLBCL
Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly has a conditional marketing authorisation
- further data awaited.
You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.
Adverse event reporting information can be found at the bottom of this page.
FRONTIERS is a programme of AbbVie promotional events and resources for GB healthcare professionals involved in the management of haematological malignancies.
Develop your knowledge with FRONTIERS events, insights & resources
Learn from leading experts and practice pioneers
AbbVie’s FRONTIERS presents ‘Embracing a new era of bispecific innovation in management of R/R DLBCL after 2 or more lines of systemic therapy’.
This event will take place in London on 8th March 2024. It is open to GB healthcare professionals involved in the management of patients with DLBCL.
FRONTIERS is a programme of AbbVie promotional events and resources for GB healthcare professionals involved in the management of haematological malignancies.
Develop your knowledge with FRONTIERS events, insights & resources
Learn from leading experts and practice pioneers
AbbVie’s FRONTIERS presents ‘Embracing a new era of bispecific innovation in management of R/R DLBCL after 2 or more lines of systemic therapy’.
This event will take place in London on 8th March 2024. It is open to GB healthcare professionals involved in the management of patients with DLBCL.
Downloadable Resources
Abbreviations
R/R=relapsed/refractory.
UK-EPCOR-230167. Date of preparation: January 2024.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]
